Becotatug

贝柯妥塔单抗

Report date: 2026/02/28 20:00:37

Base Information

Drug NameBecotatug
Drug Alias Name重组人源化抗表皮生长因子受体单克隆抗体注射液JMT-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungRectal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Jmt-Bio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdShanghai Jmt-Bio Inc
Inactive CompaniesPeking University
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungRectal Neoplasms +[6] 
Inactive IndicationsEsophageal Squamous Cell Carcinoma

Other Information

ATC CodeN/A
Related LinksN/A